Megan E B Clowse1, Amanda M Eudy1, Elizabeth Kiernan2, Matthew R Williams3, Bonnie Bermas4, Eliza Chakravarty5, Lisa R Sammaritano6, Christina D Chambers7, Jill Buyon8. 1. Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC. 2. Department of Pediatrics, Division of Dysmorphology and Teratology, University of California San Diego, San Diego, CA. 3. Pediatric Cardiology and Cardiovascular Surgery, Rady Children's Hospital, University of California San Diego, San Diego, CA. 4. Division of Rheumatic Diseases, UT Southwestern, Dallas, TX. 5. Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK. 6. Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY. 7. Department of Pediatrics, University of California San Diego, San Diego, CA. 8. Division of Rheumatology, New York University School of Medicine, NY, USA.
Abstract
Objective: To survey an international sample of providers to determine their current practices for the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro/SSA antibodies. Methods: A survey was designed by the organizing committee of the 9th International Conference of Reproduction, Pregnancy and Rheumatic Diseases. It was sent to attendants of the conference and authors of recent publications or abstracts at ACR 2012, 2013 or 2014 on rheumatic diseases and pregnancy. Results: In anti-Ro/SSA positive women, 80% of 49 respondents recommended screening by serial fetal echocardiogram (ECHO), with most starting at week 16 (59%) and stopping at week 28 (25%), although the time to stop varied widely. For women without a prior infant with neonatal lupus, respondents recommend every other week (44%) or weekly (28%) fetal ECHOs. For women with a prior infant with neonatal lupus, 80% recommend weekly fetal ECHOs. To prevent CHB, HCQ was recommended by 67% of respondents and most would start pre-pregnancy (62%). Respondents were asked about medications to treat varying degrees of CHB in a 20-week pregnant, anti-Ro and La positive SLE patient. For first degree, respondents recommended starting dexamethasone (53%) or HCQ (43%). For second degree, respondents recommended starting dexamethasone (88%). For third degree, respondents recommended starting dexamethasone (55%) or IVIg (33%), although 27% would not start treatment. Conclusion: Despite the absence of official guidelines, many physicians with a focus on pregnancy and rheumatic disease have developed similar patterns in the screening, prevention and treatment of CHB.
Objective: To survey an international sample of providers to determine their current practices for the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro/SSA antibodies. Methods: A survey was designed by the organizing committee of the 9th International Conference of Reproduction, Pregnancy and Rheumatic Diseases. It was sent to attendants of the conference and authors of recent publications or abstracts at ACR 2012, 2013 or 2014 on rheumatic diseases and pregnancy. Results: In anti-Ro/SSA positive women, 80% of 49 respondents recommended screening by serial fetal echocardiogram (ECHO), with most starting at week 16 (59%) and stopping at week 28 (25%), although the time to stop varied widely. For women without a prior infant with neonatal lupus, respondents recommend every other week (44%) or weekly (28%) fetal ECHOs. For women with a prior infant with neonatal lupus, 80% recommend weekly fetal ECHOs. To prevent CHB, HCQ was recommended by 67% of respondents and most would start pre-pregnancy (62%). Respondents were asked about medications to treat varying degrees of CHB in a 20-week pregnant, anti-Ro and La positive SLEpatient. For first degree, respondents recommended starting dexamethasone (53%) or HCQ (43%). For second degree, respondents recommended starting dexamethasone (88%). For third degree, respondents recommended starting dexamethasone (55%) or IVIg (33%), although 27% would not start treatment. Conclusion: Despite the absence of official guidelines, many physicians with a focus on pregnancy and rheumatic disease have developed similar patterns in the screening, prevention and treatment of CHB.
Authors: Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy Journal: Circulation Date: 2008-05-15 Impact factor: 29.690
Authors: Robert D Tunks; Megan E B Clowse; Stephen G Miller; Leo R Brancazio; Piers C A Barker Journal: Am J Obstet Gynecol Date: 2012-09-28 Impact factor: 8.661
Authors: Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta Journal: Nat Rev Rheumatol Date: 2015-03-24 Impact factor: 20.543
Authors: C N Pisoni; A Brucato; A Ruffatti; G Espinosa; R Cervera; M Belmonte-Serrano; J Sánchez-Román; F G García-Hernández; A Tincani; M T Bertero; A Doria; G R V Hughes; M A Khamashta Journal: Arthritis Rheum Date: 2010-04
Authors: Robert M Clancy; David Alvarez; Elena Komissarova; Franck J Barrat; Jordan Swartz; Jill P Buyon Journal: J Immunol Date: 2010-01-20 Impact factor: 5.422
Authors: Peter S Fischbach; Patricio A Frias; Margaret J Strieper; Robert M Campbell Journal: Congenit Heart Dis Date: 2007 Jul-Aug Impact factor: 2.007
Authors: Jill M Steiner; Erwin N Oechslin; Gruschen Veldtman; Craig S Broberg; Karen Stout; James Kirkpatrick; Adrienne H Kovacs Journal: Cardiol Young Date: 2020-02-14 Impact factor: 1.093
Authors: Sara De Carolis; Cristina Garufi; Ester Garufi; Maria Pia De Carolis; Angela Botta; Sara Tabacco; Silvia Salvi Journal: Front Pediatr Date: 2020-12-22 Impact factor: 3.418